- Home
- PFLT vs KURA Comparison
PFLT vs KURA Comparison
Compare PFLT & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PFLT | KURA |
|---|---|---|
| Founded | 2010 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 899.9M | 1.0B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PFLT | KURA |
|---|---|---|
| Price | $9.26 | $10.20 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 11 |
| Target Price | $10.75 | ★ $25.00 |
| AVG Volume (30 Days) | 880.3K | ★ 1.7M |
| Earning Date | 02-09-2026 | 11-04-2025 |
| Dividend Yield | ★ 13.50% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.72 | N/A |
| Revenue | ★ $261,427,000.00 | $104,029,000.00 |
| Revenue This Year | $11.66 | $138.16 |
| Revenue Next Year | N/A | $66.98 |
| P/E Ratio | $12.70 | ★ N/A |
| Revenue Growth | ★ 40.28 | N/A |
| 52 Week Low | $8.40 | $5.41 |
| 52 Week High | $11.50 | $12.49 |
Technical Indicators
Market Signals| Indicator | PFLT | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 53.48 | 44.49 |
| Support Level | $9.01 | $9.68 |
| Resistance Level | $9.14 | $11.28 |
| Average True Range (ATR) | 0.15 | 0.49 |
| MACD | -0.02 | -0.06 |
| Stochastic Oscillator | 42.28 | 31.56 |
Price Performance
Historical ComparisonAbout PFLT PennantPark Floating Rate Capital Ltd.
PennantPark Floating Rate Capital Ltd is a closed-end, externally managed, non-diversified investment company. Its investment objectives are to generate both current income and capital appreciation by investing in Floating Rate Loans and other investments made to U.S. middle-market companies. The company believes that Floating Rate Loans to U.S. middle-market companies offer attractive risk-reward to investors due to the limited amount of capital available for such companies and the potential for rising interest rates. The company generates revenue in the form of interest income on the debt securities and dividends.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.